Clinical trials are essential to advancing medicine, yet trial protocols are too often built around an “ideal” patient profile, perfectly adherent, available, and uncomplicated, but this patient rarely exists in real life. But real people are more complex. They have jobs, families, comorbidities, and lives that don’t stop when a trial begins.
Designing studies for a perfect patient might look good on paper. It promises clean data and easy comparisons. But it does not reflect the reality of who gets sick and who needs treatment.
Unrealistic eligibility criteria and rigid visit schedules reduce enrollment and skew participation toward the few who can fit the mold, undermining clinical trial diversity. They also fail to prepare treatments for the real-world challenges they will face. To move forward, we must reframe clinical research to embrace the realities of real patients. That shift starts with more inclusive clinical study recruitment.
Designing for Complexity, not Simplicity
Many clinical trial designs are shaped by what is easiest to measure, not what patients actually experience. Researchers often exclude patients with additional health conditions, mental health concerns, or logistical challenges. The goal is to avoid variability. But in doing so, they exclude the very people most likely to need the intervention being tested.
When real patients do manage to enrol, they can struggle to stay. Long visits, strict schedules, and overwhelming paperwork take a toll. Some patients miss appointments or drop out entirely. Others are removed for failing to meet rigid compliance expectations. These losses are often seen as unavoidable, but they are symptoms of a system that was never built around the people it is meant to serve.
Every exclusion narrows the scope of the trial. It makes findings less relevant to the broader population. It can also mask important safety issues or lead to overestimated benefits. In the end, the treatment may not perform as expected once approved.
The myth of the perfect patient also impacts how protocols are written. Protocol designs that ignore the complexity of daily life, jobs, caregiving, transportation, or comorbidities, lead to higher dropout rates and incomplete data.
Clinical Study Recruitment Needs a Reset
If we want to reach more patients, we need to meet them where they are. That begins with making trials more accessible, understandable, and compatible with real life. Right now, many clinical study recruitment strategies only succeed in reaching the most resourced and well-connected individuals. This leaves out the majority and limits what research can achieve.
More inclusive recruitment means expanding eligibility. It means accounting for common comorbidities and life situations instead of treating them as disqualifiers. It also means rethinking outreach. Instead of expecting patients to find the study, researchers must bring the study to the patient.
This involves working with community leaders, using patient-friendly language, and building trust long before a trial starts. It also means re-evaluating how studies are introduced and explained. Patients are more likely to take part when they feel understood, respected, and clearly informed.
Technology can help, but only if used wisely. Digital recruitment tools must be designed for ease, not just efficiency. They should consider barriers like digital literacy, language access, and platform fatigue. A tool that looks good to researchers may fall flat if it doesn’t connect with patients’ everyday experiences.
Real Inclusion Requires Clinical Trial Diversity
It’s not enough to increase participant numbers. We need to ensure those numbers reflect the full range of people affected by a condition. Clinical trial diversity improves the quality of data, the fairness of treatment access, and the safety of outcomes. But right now, trial populations often skew towards the same small segment.
This happens for many reasons. Strict inclusion criteria, geographic limitations, and cultural mistrust all play a role. So does a lack of representation in the teams designing and leading the trials. Changing this requires a conscious effort to prioritise diversity from the start.
Community partnerships are key. When researchers engage with trusted organisations and leaders, they build credibility. This opens doors that would otherwise remain closed. It also helps researchers better understand the cultural, financial, and logistical barriers patients face.
Flexible study designs also support inclusion. Trials that allow virtual visits, local lab work, or adjusted schedules make it easier for more people to take part. These adaptations do not weaken the science. They strengthen it by making the results more generalisable and relevant.
Building Around Real Patient Lives
A better trial is one that fits into a patient’s life, not one that expects the patient to reshape their world around it. This means designing protocols with input from the people who will actually live them. Centering real patient experiences in trial design creates more feasible studies, improves recruitment, and produces data that is truly representative.
Patient advisory boards, focus groups, and co-design workshops help researchers understand what works and what doesn’t. They provide feedback on visit frequency, communication style, and support tools. They challenge assumptions and point out blind spots. Most importantly, they bring lived experience into a process that is too often led by theory alone.
Real-world design also considers practical needs. Are appointments offered outside of working hours? Is transport or childcare support available? Are instructions clear, and is help offered when problems arise? These details can mean the difference between success and failure.
Technology plays a supporting role here too. Platforms for reminders, updates, and support can make the trial experience smoother. So can real-time feedback tools that let patients share how they’re doing. These innovations help build a relationship of trust and care between patients and researchers.
Reforming how we design trials means moving from “perfect patients” to realistic protocols that reflect the messy, human reality of living with illness. Let’s speak about creating a system that reflects and respects the people it depends on.
Keith Berelowitz | Founder & CEO
Keith Berelowitz is the Founder of pRxEngage, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.
